Promoter hypermethylation and quantitative expression analysis of CDKN2A (p14ARF and p16INK4a) gene in esophageal squamous cell carcinoma

Anticancer Research

Volumn 27, Issue 5 A, 2007, Pages 3345-3353

  Ito, Shuhei ^a,d   Ohga, Takefumi ^a   Saeki, Hiroshi ^a   Watanabe, Masayuki ^a   Kakeji, Yoshihiro ^a   Morita, Masaru ^a   Yamada, Tomomi ^c   Maehara, Yoshihiko ^a,b  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

Author keywords

Esophageal squamous cell carcinoma; Methylation; Methylation specific PCR; p14ARF; p16INK4a; Prognosis; Real time quantitative RT PCR

Indexed keywords

PROTEIN P14ARF; PROTEIN P16INK4A;

ARTICLE; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE EXPRESSION; GENE REPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; METHYLATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION; GENES, P16; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 35348965692     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Lerut T, Nafteux P, Moons J, Coosemans W, Decker G, De Leyn P, Van Raemdonck D and Ectors N: Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg 240: 962-974, 2004.
2. Tsurumaru M, Kajiyama Y, Udagawa H and Akiyama H: Outcomes of extended lymph node dissection for squamous cell carcinoma of the thoracic esophagus. Ann Thorac Cardiovasc Surg 7: 325-329, 2001.
3. Mandard AM, Hainaut P and Hollstein M: Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutat Res 462: 335-342, 2000.
4. Chin L, Pomerantz J and DePinho RA: The INK4a/ARF tumor suppressor: one gene-two products-two pathways. Trends Biochem Sci 23: 291-296, 1998.
5. ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res 61: 2816-2821, 2001.
6. Fulci G, Labuhn M, Maier D, Lachat Y, Hausmann O, Hegi ME, Janzer RC, Merlo A and Van Meir EG: p53 gene mutation and INK4a-ARF deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 19: 3816-3822, 2000.
7. Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-Cardo C, Horner JW 2nd and DePinho RA: Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 11: 2822-2834, 1997.
8. Holland EC, Hively WP, DePinho RA and Varmus HE: A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 12: 3675-3685, 1998.
9. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR and Lowe SW: INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13: 2670-2677, 1999.
10. Jones PA and Laird PW: Cancer epigenetics comes of age. Nature Genet 21: 163-167, 1999.
11. Esteller M, Corn PG, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229, 2001.
12. Sugimura T and Ushijima T: Genetic and epigenetic alterations in carcinogenesis. Mutat Res 462: 235-246, 2000.
13. Momparler RL and Bovenzi V: DNA methylation and cancer. J Cell Physiol 183: 145-154, 2000.
14. Nie Y, Liao J, Zhao X, Song Y, Yang GY, Wang LD and Yang CS: Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma. Carcinogenesis 23: 1713-1720, 2002.
15. Esteve A, Martel-Planche G, Sylla BS, Hollstein M, Hainaut P and Montesano R: Low frequency of p16/CDKN2 gene mutation in esophageal carcinomas. Int J Cancer 66: 301-304, 1996.
16. INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res 5: 2704-2713, 1999.
17. Gamieldien W, Victor TC, Mugwanya D, Stepien A, Gelderblom WC, Marasas WF, Geiger DH and van Helden PD: p53 and p16/CDKN2 gene mutations in esophageal tumors from a high-incidence area in South Africa. Int J Cancer 78: 544-549, 1998.
18. Morita M, Kuwano H, Ohno S, Sugimachi K, Seo Y, Tomoda H, Furusawa M and Nakashima T: Multiple occurrence of carcinoma in the upper aerodigestive tract associated with esophageal cancer: reference to smoking, drinking and family history. Int J Cancer 58: 207-210, 1994.
19. Miyazaki M, Ohno S, Futatsugi M, Saeki H, Ohga T and Watanabe M: The relationship of alcohol consumption and cigarette smoking to the multiple occurrence of esophageal dysplasia and squamous cell carcinoma. Surgery 131: 7-13, 2002.
20. Saeki H, Ohno S, Araki K, Egashira A, Kawaguchi H, Ikeda Y, Morita M, Kitamura K and Sugimachi K: Alcohol consumption and cigarette smoking in relation to high frequency of p53 protein accumlation in oesophageal squamous cell carcinoma in the Japanese. Br J Cancer 82: 1892-1894, 2000.
21. INK4a methylation and p53 mutational status. Cancer Res 60: 129-133, 2000.
22. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996.
23. CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 16: 859-867, 1996.
24. Heid CA, Stevens J, Livak KJ and Williams PM: Real time quantitative PCR. Genome Res 6: 986-994, 1996.
25. Tokunaga E, Maehara Y, Oki E, Koga T, Kakeji Y and Sugimachi K: Application of quantitative RT-PCR using "TaqMan" technology to evaluate the expression of CK 18 mRNA in various cell lines. J Exp Clin Cancer Res 19: 375-381, 2000.
26. Marchuk D, Drumm M, Saulino A and Collins FS: Construction of T-vectors, a rapid and general system for direct cloning of unmodified PCR products. Nucleic Acids Res 19: 1154, 1991.
27. Morita M, Saeki H, Mori M, Kuwano H and Sugimachi K: Risk factors for esophageal cancer and the multiple occurrence of carcinoma in the upper aerodigestive tract. Surgery 131: S1-6, 2002.
28. ARF) and p53 genes are major targets for inactivation. Carcinogenesis 23: 645-655, 2002.
29. Hibi K, Taguchi M, Nakayama H, Takase T, Kasai Y, Ito K, Akiyama S and Nakao A: Molecular detection of p16 promoter methylation in the serum of patient with esophageal squamous cell carcinoma. Clin Cancer Res 7: 3135-3138, 2001.
30. Ito S, Ohga T, Saeki H, Nakamura T, Watanabe M, Tanaka S, Kakeji Y and Maehara Y: p53 Mutation profiling of multiple esophageal carcinoma using laser capture microdissection to demonstrate field carcinogenesis. Int J Cancer 113: 22-28, 2005.
31. INK4a and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 61: 3419-3424, 2001.
32. Belinsky SA, Palmisano WA Gilliland FD, Crooks LA, Divine KK, Winters SA Grimes MJ, Harms HJ, Tellez CS, Smith TM, Moots PP, Lechner JF, Stidley CA and Crowell RE: Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 62: 2370-2377, 2002.
33. Esteller M: CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21: 5427-5440, 2002.
34. ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 11: 159-168, 2001.
35. Esteller M, Fraga MF, Paz MF, Campo E, Colomer D, Novo FJ, Calasanz MJ, Galm O, Guo M, Benitez J and Herman JG: Cancer epigenetics and methylation. Science 297: 1807-1808, 2002.
36. Maesawa C, Tamura G, Nishizuka S, Ogasawara S, Ishida K, Terashima M, Sakata K, Sato N, Saito K and Satodate R: Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma. Cancer Res 56: 3875-3878, 1996.
37. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Agirre X, Barrios M, Navarro G, Molina FJ, Calasanz MJ, Prosper F, Heiniger A and Torres A: Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 104: 2492-2498, 2004.
38. ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course. Clin Cancer Res 9: 4884-4890, 2003.
39. Dominguez G, Silva J, Garcia JM, Silva JM, Rodriguez R, Munoz C, Chacon I, Sanchez R, Carballido J, Colas A, Espana P and Bonilla F: Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors. Mutat Res 530: 9-17, 2003.
40. Haller F, Gunawan B, von Heydebreck A, Schwager S, Schulten HJ, Wolf-Salgo J, Langer C, Ramadori G, Sultmann H and Fuzesi L: Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors. Clin Cancer Res 11: 6589-6597, 2005.
41. ARF protein expression is a predictor of both relapse and survival in squamous cell carcinoma of the anterior tongue. Clin Cancer Res 11: 4107-4116, 2005
42. INK4a expression in resected non-small cell lung tumors. Cancer Res 56: 3415-3420, 1996.
43. Hu YX, Watanabe H, Ohtsubo K, Yamaguchi Y, Ha A, Okai T and Sawabu N: Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Clin Cancer Res 3: 1473-1477, 1997.
44. Takeuchi H, Ozawa S, Ando N, Shih CH, Koyanagi K, Ueda M and Kitajima M: Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus. Clin Cancer Res 3: 2229-2236, 1997.
45. Guner D, Sturm I, Hemmati P, Hermann S, Hauptmann S, Wurm R, Budach V, Dorken B, Lorenz M and Daniel PT: Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis. Int J Cancer 103: 445-454, 2003.